NCT06409195 2024-05-10
A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers
DermBiont, Inc.
Phase 2 Recruiting
Clinical Trials
10 trialsNCT02462187 2023-04-06
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
Novan, Inc.
Phase 2 Completed
NCT02724254 2018-07-20
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
Vaxart
Phase 2 Completed
NCT02596074 2017-08-03
Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN
Maruho Co., Ltd.
Phase 2 Completed
NCT02307487 2017-06-16
Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients
UroGen Pharma Ltd.
Phase 2 Completed
NCT02796066 2017-04-26
TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris
Thesan Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT02849262 2017-03-31
Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts
Maruho Co., Ltd.
Phase 2 Completed
NCT00852137 2015-03-06
A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis
Peplin
Phase 2 Completed
NCT00343187 2011-05-30
A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash
Allergan
Phase 2 Terminated
NCT01214564 2011-01-25
Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis
Peplin
Phase 2 Completed